

Rev 1: September 2018

FSN Ref: FSN-2022-005 FSCA Ref: FSN-2022-005

Date: 18:MAY:2022

<u>Urgent Field Safety Notice</u> <u>Device Commercial Name</u>

For Attention of *: Lab Managers

Contact details of local representative (name, e-mail, telephone, address etc.)*

E.mail: mbd.vigilance@thermofisher.com Telephone: +44(0) 1256841144

Fax: +44(0) 1256 479525

The world leader in serving science

Rev 1: September 2018 FSN Ref: FSN-2022-005

FSCA Ref: FSN-2022-005

Urgent Field Safety Notice (FSN) Device Commercial Name Risk addressed by FSN

	1. Information on Affected Devices*				
1.	1. Device Type(s)*				
	IVD				
1.	2. Commercial name(s)				
	Thermo Scientific™ MicroTest™ M4RT 3mL w/o Beads NP Swab Kit 100/pk				
1.	Unique Device Identifier(s) (UDI-DI)				
	00842558109527				
1.	4. Primary clinical purpose of device(s)*				
	Remel MicroTest™ M4RT® is a liquid medium recommended for the transport of				
	clinical specimens to the laboratory for microbiological procedures for viral and				
	chlamydial agents.				
L_					
1.	5. Device Model/Catalogue/part number(s)*				
	R12705				
1.	6. Software version				
	N/A				
1.	7. Affected serial or lot number range				
	472505				
1.	Associated devices				
	N/A				

2. Reason for Field Safety Corrective Action (FSCA)*					
2.	Description of the product problem*				
	An internal technical investigation has confirmed that Thermo Scientific™ MicroTes M4RT 3mL w/o Beads NP Swab Kit 100/pk R12705 Lot 472505 contained the incorr swab component. The kit contained a standard-size flocked swab, rather than nasopharyngeal swab. Performance of the M4RT tube is unaffected.				
2.	2. Hazard giving rise to the FSCA*				
	Very low.				
2.	3. Probability of problem arising				
	Low.				
2.	4. Predicted risk to patient/users				
	There should be no immediate or long-term health consequences due to this kit containing the incorrect swab. The incorrect swab is readily distinguishable from the nasopharyngeal swab. Additionally, there was no objective evidence that the performance of the transport medium is in any way affected. Therefore, the clinical risk should be considered very low to negligible.				
2.	5. Further information to help characterise the problem				
	N/A				
2.	6. Background on Issue				
	An internal investigation has found that R12705 Lot 472505 contained the incorrect				
	swab component.				
2.	7. Other information relevant to FSCA				



The world leader in serving science

Rev 1: September 2018 FSN Ref: FSN-2022-005

FSCA Ref: FSN-2022-005

Lot. 472505 with the expiry of 30-Mar-2024

	3. Type of Action to mitigate the Risk*						
3.	1.	. Action To Be Taken by the User*					
		□ Quantify Device □ Q	rantine Device Return Device	□ Destroy Device □			
	☐ On-site device modification/inspection						
		☐ Follow patient management recommendations					
		☐ Take note of amendment/reinforcement of Instructions For Use (IFU)					
		☐ Other ☐ None					
3.	2.	By when should the action be completed?	Immediately				
3.	3.	. Particular considerations for: IVD					
		Is follow-up of patients or review of patients' previous results recommended? No					
		Follow-up not required since performance of M4RT tube is unaffected.					
3.	4.	Is customer Reply Require		Yes			
_	(If	yes, form attached specifyir	ng deadline for return)				
3.	Э.	Action Being Taken by the	Manuracturer				
		□ Product Removal □	☐ On-site device modification/insp	ection			
			☐ IFU or labelling change				
		☐ Other	□ None				
3	6.	By when should the action be completed?	As soon as possible				
3.	7.	Is the FSN required to be communicated to the patient No /lay user?					
3	8.			•			
	user in a patient/lay or non-professional user information letter/sheet?			etter/sheet?			
	l	N/A					



Rev 1: September 2018 FSN Ref: FSN-2022-005

FSCA Ref: FSN-2022-005

	4. General Information*					
4.	1. FSN Type*	New				
4.	For updated FSN, reference number and date of previous FSN	N/A				
4.	3. For Updated FSN, key new inform	nation as follows:				
	N/A					
4.	4. Further advice or information already expected in follow-up FSN? *	Not planned yet				
4	5. If follow-up FSN expected, what is the further advice expected to relate to:					
	N/A					
4	Anticipated timescale for follow- up FSN	N/A				
4.	7. Manufacturer information (For contact details of local representative refer to page 1 of this FSN)					
	a. Company Name	Remel Inc.				
	b. Address	12076 Santa Fe Trail Drive Lenexa KS 66215				
	c. Website address	www.thermofisher.com				
4.	8. The Competent (Regulatory) Authority of your country has been informed about this communication to customers. *					
4.	9. List of attachments/appendices:	Customer Response Form				
4.	10. Name					
	Signature					

Transmission of this Field Safety Notice This notice needs to be passed on all those who need to be aware within your organisation or to any organisation where the potentially affected devices have been transferred. (As appropriate) Please transfer this notice to other organisations on which this action has an impact. (As appropriate) Please maintain awareness on this notice and resulting action for an appropriate period to ensure effectiveness of the corrective action. Please report all device-related incidents to the manufacturer, distributor or local representative, and the national Competent Authority if appropriate, as this provides important feedback.*